Impact of Preoperative Embolization Materials on Surgery for Sizeable Shamblin Type Ⅱ/Ⅲ Carotid Body Tumors
10.11714/jsysu.med.YX20260068
- VernacularTitle:术前栓塞材料对3 cm以上的Shamblin Ⅱ/Ⅲ型颈动脉体瘤外科手术的影响
- Author:
Nan LI
1
;
Lexi LI
1
;
Jianyong YANG
2
;
Yonghui HUANG
2
Author Information
1. Department of Interventional Radiology， Guangzhou First People’s Hospital， Guangzhou 510000， China
2. Department of Interventional Radiology， The First Affiliated Hospital， Sun Yat-sen University， Guangzhou 510080， China
- Publication Type:Journal Article
- Keywords:
carotid body tumor;
transarterial embolization;
embolic materials;
surgical resection;
impact
- From:
Journal of Sun Yat-sen University(Medical Sciences)
2026;47(5):931-937
- CountryChina
- Language:Chinese
-
Abstract:
ObjectiveTo explore the effects of different embolic materials for preoperative transarterial embolization （TAE） on surgical resections of sizeable （＞3 cm） Shamblin Ⅱ/Ⅲ carotid body tumors （CBTs） MethodsThis study retrospectively analyzed the data of patients with Shamblin type Ⅱ/Ⅲ carotid body tumors >3 cm in size who underwent TAE at our hospital between January 2010 and August 2025. Based on the adopted embolic agents， the patients were divided into two groups： temporary embolization group （TEG） and permanent embolization group （PEG）. General clinical data， periprocedural details， and postoperative outcomes were collected and compared between the two groups. ResultsA total of 50 patients with 50 lesions were included （n=25 in the TEG and n=25 in PEG group）. Tumor sizes were comparable between the two groups ［（41.22 vs. 42.13） mm， P=0.989］. For the TEG compared with PEG， intraoperative blood loss was （388.19 vs. 155.90） mL （P＜0.001） and operative time was （254.01 vs. 162.22） mins （P=0.007）. The intraoperative vascular reconstruction rate was 16% vs. 12% （P=0.684）， and the complication rate was 36% vs. 12% （P=0.047） in the TEG and PEG. ConclusionsOur results indicate that the use of permanent embolic agents during TAE is optimal. These agents are superior to temporary embolic agents in terms of intraoperative blood loss， operative time， and improved surgical field visualization， which thereby facilitate the surgical resection of Shamblin type Ⅱ/Ⅲ CBTs while reducing postoperative complications.
